ArtAssist序贯加压生物力学装置作为无选项慢性肢体威胁性缺血保肢策略:15年单中心队列的健康经济学与Q-TWiST分析
该单中心纵向队列纳入428例不可重建的慢性肢体威胁性缺血(CLTI)患者,接受ArtAssist序贯加压生物力学装置(SCBD)治疗。
要点
- ArtAssist SCBD在不可重建CLTI中实现85%粗保肢率与约95%的5年估计保肢率。
- 与一期截肢相比,90天租用装置使总支出减少六倍,每例节省76,500欧元。
核心结论
- 总体粗保肢率85%,估计5年保肢率约95%,为已报告的最大单中心队列。
- 研究结果支持将ArtAssist SCBD普遍配置用于不可重建的CLTI。
研究设计与样本
- 单中心三级中心纵向队列分析,纳入428例不可重建的CLTI患者,接受ArtAssist SCBD治疗,时间跨度为2008年1月至2025年6月。
- 采用Kaplan-Meier分析保肢率、多变量Cox回归分析大截肢、竞争风险分析,并使用同期成本数据进行健康经济学建模。
主要发现
- 总体粗保肢率(免于大截肢)为85%(294/347例)。
- 末次随访时48%的患者存活且未发生大截肢。
- Kaplan-Meier估计5年保肢率为95%;将死亡作为竞争事件后,5年大截肢累积发生率为8%。
临床怎么用
- 对于不可重建的CLTI患者,可考虑使用ArtAssist SCBD作为保肢策略,以降低费用并改善质量调整生存。
- 男性、高血压和缺血性心脏病患者大截肢或保肢失败风险较高,应加强监测。
- 合并症负担与保肢失败存在剂量-反应关系,提示需综合管理合并症。
局限性
- 为单中心队列研究,结果外推需谨慎。
- 原文未报告随机对照设计,存在选择偏倚可能。
- 原文未报告长期随访中装置依从性及不良事件数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major lower limb amputation for no-option chronic limb-threatening ischaemia (CLTI) costs the Irish Health Service Executive (HSE) a median €88,820 per patient; long-term health economic and quality-adjusted survival evidence for ArtAssist SCBD is lacking. METHODS: Longitudinal cohort analysis of 428 patients with non-reconstructible CLTI managed with ArtAssist SCBD at a single tertiary centre (January 2008-June 2025). Primary endpoints were limb salvage, cost-effectiveness versus primary amputation, and Q-TWiST. Kaplan-Meier analysis of limb salvage, multivariable Cox regression for major amputation, competing-risks analysis, and health economic modelling using contemporaneous cost data were performed. FINDINGS: Overall crude limb salvage, defined as freedom from major amputation, was achieved in 85% (294/347 patients). At last follow-up, 48% of patients were alive without major amputation. Kaplan-Meier estimated 5-year limb salvage at 95%. The cumulative incidence of major amputation at 5 years was 8% when accounting for death as a competing event, confirming durable limb preservation despite substantial long-term mortality in this elderly, comorbid population. Male sex, hypertension, and ischaemic heart disease independently predicted major amputation or limb-salvage failure (HRs 1·70, 1·80, 1·71; all P ≤ ·012). Comorbidity burden showed a dose-response relationship (P = ·008). 90-day rental (€1,373/patient) reduced total expenditure six-fold versus primary amputation (€5·3M vs €30·8M), saving €76,500/patient. Q-TWiST yielded a gain of 3·37 QALYs per patient; ICER €21,900/QALY confirms a dominant strategy. INTERPRETATION: ArtAssist SCBD achieves a six-fold reduction in costs versus primary amputation, +3·37 QALYs/patient, and an ICER of €21,900/QALY a dominant strategy supported by durable limb preservation, with 85% overall crude limb salvage and an estimated 5-year limb salvage of approximately 95% in the largest single-centre cohort reported. These findings support universal commissioning of ArtAssist SCBD for non-reconstructible CLTI.
引用
- Sultan S, Tsapara AS, Harrison P, et al. ArtAssist Sequential Compression Biomechanical Device as a Cost-Dominant Limb-Salvage Strategy for No-Option Chronic Limb-Threatening Ischaemia: A Decade and Half, Single-Centre Cohort Study with Health Economic and Q-TWiST Analysis. J Vasc Surg. 2026. PMID: 42887569. doi:10.1016/j.jvs.2026.09.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。